Gradual dose increases If appropriate, the dose may be increased gradually over time under clinician supervision to improve treatment effectiveness and tolerability
Demonstrating safety and effectiveness necessitates rigorous trials with reproductive endpoints, long-term offspring follow-up, and pharmacovigilance systems
According to FDA labeling, nausea occurs in approximately 44% of patients on Wegovy (2.4 mg for weight management) and 15-20% on lower diabetes doses, with vomiting, diarrhea, constipation, and abdominal pain also common
The agency permits some unapproved drugs to be marketed if they are relied on by health care professionals to treat serious medical conditions when there is no FDA-approved drug to treat the condition or there is insufficient supply of FDA-approved drugs. Given these complexities, ideal patient candidates for Retatrutide include individuals with significant obesity, persistent insulin resistance, and metabolic syndrome who have not adequately responded to other medically supervised weight-loss strategies and who clearly understand the investigational status of the medication
Because TB-500 is often injected, some redness at the site can occur